UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

NCT02140840 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped PI left institution

Conditions

Interventions

Sponsor

University of Arkansas